Home
Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

Today’s Highlights October 6, 2021

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002
Intellia Therapeutics (NTLA) announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE).
About Hereditary . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
October 6, 2021

Other Articles